Update on antifungal treatment of invasive Candida and Aspergillus infections (Q45017863)

8 December 2017

Update on antifungal treatment of invasive Candida and Aspergillus infections (English)

1 reference

8 December 2017

Maschmeyer G

1

1 reference

PubMed ID

15310328

8 December 2017

Ruhnke M

series ordinal

2

1 reference

8 December 2017

1 August 2004

1 reference

8 December 2017

1 reference

8 December 2017

47

1 reference

8 December 2017

7

1 reference

8 December 2017

263-276

1 reference

Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients

8 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Diagnosis of invasive fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Treatment of invasive aspergillosis with itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Resistance of Candida species to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

Prophylactic antifungal therapy in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2004.01003.X

10.1111/J.1439-0507.2004.01003.X

21 January 2018

Identifiers

DOI

1 reference

8 December 2017

1 reference

PubMed ID

15310328